- Home
- LXP vs NVAX Comparison
LXP vs NVAX Comparison
Compare LXP & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXP
- NVAX
- Stock Information
- Founded
- LXP 1993
- NVAX 1987
- Country
- LXP United States
- NVAX United States
- Employees
- LXP N/A
- NVAX N/A
- Industry
- LXP Real Estate Investment Trusts
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LXP Real Estate
- NVAX Health Care
- Exchange
- LXP Nasdaq
- NVAX Nasdaq
- Market Cap
- LXP 2.5B
- NVAX 1.4B
- IPO Year
- LXP 1993
- NVAX 1995
- Fundamental
- Price
- LXP $8.33
- NVAX $8.38
- Analyst Decision
- LXP Buy
- NVAX Buy
- Analyst Count
- LXP 3
- NVAX 6
- Target Price
- LXP $11.50
- NVAX $17.83
- AVG Volume (30 Days)
- LXP 2.2M
- NVAX 4.8M
- Earning Date
- LXP 02-13-2025
- NVAX 02-26-2025
- Dividend Yield
- LXP 6.45%
- NVAX N/A
- EPS Growth
- LXP N/A
- NVAX N/A
- EPS
- LXP 0.06
- NVAX N/A
- Revenue
- LXP $340,563,000.00
- NVAX $885,193,000.00
- Revenue This Year
- LXP N/A
- NVAX N/A
- Revenue Next Year
- LXP $2.50
- NVAX N/A
- P/E Ratio
- LXP $127.46
- NVAX N/A
- Revenue Growth
- LXP 0.56
- NVAX N/A
- 52 Week Low
- LXP $7.65
- NVAX $3.60
- 52 Week High
- LXP $10.57
- NVAX $23.86
- Technical
- Relative Strength Index (RSI)
- LXP 48.68
- NVAX 45.04
- Support Level
- LXP $8.11
- NVAX $8.30
- Resistance Level
- LXP $8.50
- NVAX $9.77
- Average True Range (ATR)
- LXP 0.20
- NVAX 0.56
- MACD
- LXP 0.04
- NVAX -0.06
- Stochastic Oscillator
- LXP 50.72
- NVAX 12.67
About LXP LXP Industrial Trust (Maryland REIT)
LXP Industrial Trust is a real estate investment trust principally involved in the ownership of equity and debt investments in single-tenant properties and land throughout the United States. Majority of the revenue is earned through rental revenue.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.